Relypsa Appoints Garland President, CEO Orwin to Step Away in June

Gastrointestinal drugs developer Relypsa has promoted Scott Garland to the position of president. Garland had previously served as senior vice president and chief commercial officer of the Redwood City, Calif-based company. Before joining Relypsa, Garland was vice president and chief commercial officer of South San Francisco-based Exelixis (NASDAQ: [[ticker:EXEL]]). His career also includes posts at Genentech and Amgen (NASDAQ: [[ticker:AMGN]]).

John Orwin, who is currently Relypsa’s president and CEO, will continue in his position until June 30. After that date, he will move into an advisory role with Vifor Pharma, Relypsa’s Switzerland-based parent company.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.